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Significance of this study
What is already known on this subject?
 ► Hepatocellular carcinoma (HCC) is a common 
cancer with high rate of recurrence and 
mortality. HCC is widely heterogeneous and 
diverse imposing formidable challenges to 
effective treatment and personalised therapy.
 ► Tonicity-responsive enhancer-binding 
protein (TonEBP) is a critical regulator 
in many inflammatory diseases such as 
rheumatoid arthritis and atherosclerosis. While 
inflammation is intimately implicated in the 
pathogenesis of HCC, the role of TonEBP is 
unknown.
What are the new findings?
 ► TonEBP is involved at multiple steps of the 
common pathway of HCC development and 
tumour progression: cell injury, induction by 
oxidative stress and inflammation.
 ► TonEBP stimulated hepatic inflammation 
including prostaglandin E2 production which 
contributes to tumour growth and progression.
 ► Expression of TonEBP is elevated in tumours in 
more than 90% of patients with HCC regardless 
of aetiology associated.
 ► In patients with HCC who received resection, 
higher hepatic TonEBP expression is associated 
with recurrence, metastasis and survival in 
multivariate analyses.
How might it impact on clinical practice in the 
foreseeable future?
 ► Examination of TonEBP expression in hepatic 
tissues from patients who received resection of 
HCC would provide the patients with valuable 
prognostic information regarding recurrence 
and metastasis.
 ► TonEBP is an attractive target for therapeutic 
agents to prevent recurrence and metastasis as 
well as tumourigenesis.
AbSTrACT
Objectives Hepatocellular carcinoma (Hcc) is a 
common cancer with high rate of recurrence and 
mortality. Diverse aetiological agents and wide 
heterogeneity in individual tumours impede effective 
and personalised treatment. tonicity-responsive 
enhancer-binding protein (toneBP) is a transcriptional 
cofactor for the expression of proinflammatory genes. 
although inflammation is intimately associated with the 
pathogenesis of Hcc, the role of toneBP is unknown. We 
aimed to identify function of toneBP in Hcc.
Design tumours with surrounding hepatic tissues were 
obtained from 296 patients with Hcc who received 
completion resection. toneBP expression was analysed 
by quantitative reverse transcription–quantitative real-
time Pcr (rt-Pcr) and immunohfistochemical analyses 
of tissue microarrays. Mice with toneBP haplo 
deficiency, and hepatocyte-specific and myeloid-specific 
toneBP deletion were used along with Hcc and 
hepatocyte cell lines.
results toneBP expression is higher in tumours than 
in adjacent non-tumour tissues in 92.6% of patients 
with Hcc regardless of aetiology associated. the 
toneBP expression in tumours and adjacent non-tumour 
tissues predicts recurrence, metastasis and death in 
multivariate analyses. toneBP drives the expression of 
cyclo-oxygenase-2 (cOX-2) by stimulating the promoter. 
in mouse models of Hcc, three common sites of toneBP 
action in response to diverse aetiological agents leading 
to tumourigenesis and tumour growth were found: cell 
injury and inflammation, induction by oxidative stress 
and stimulation of the cOX-2 promoter.
Conclusions toneBP is a key component of the 
common pathway in tumourigenesis and tumour 
progression of Hcc in response to diverse aetiological 
insults. toneBP is involved in multiple steps along the 
pathway, rendering it an attractive therapeutic target as 
well as a prognostic biomarker.
InTrODuCTIOn
Hepatocellular carcinoma (HCC) is the sixth most 
common cancer and the second most common 
cause of cancer-related death worldwide with 
steadily increasing incidence.1 The characteristic 
high mortality  of HCC is due to a combination of 
multiple factors: difficulty in early detection, lack 
of effective treatments and extremely high rates of 
recurrence and metastasis.2 The major aetiological 
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Figure 1 Hepatic TonEBP expression is elevated in HCC and associated with postoperative recurrence and death in patients with HCC. (A–D) 
Hepatic TonEBP expression in a mouse model of HCC. (A) TonEBP mRNA levels in tumour-free normal tissues from PBS-injected animals (n=8) and 
non-tumour and tumours from DEN-injected animals (n=18). Mean+SEM, *P<0.05. (B) Immunoblots of non-tumour and tumours from seven animals. 
(C) Immunohistochemical images of TonEBP (brown) in hepatic tissues from PBS-injected or DEN-injected animals. Nuclei were counterstained with 
haematoxylin (blue). (D) Tumour number and TonEBP mRNA in non-tumour in individual animals were plotted (n=12). (E–G) TonEBP expression in 
hepatic tissues of patients with HCC. (E) Representative immunohistochemical images of TonEBP in hepatic biopsies from patients with HCC. (F) 
TonEBP mRNA in non-tumour and tumour was measured from patients with HBV- (n=23), HCV- (n=7) and alcohol-associated HCC (n=8). Tumour 
TonEBP expression of each patient was normalised to its non-tumour region TonEBP expression. Mean+SEM, *P<0.05 compared with corresponding 
non-tumour. (G) Non-tumour TonEBP mRNA was measured from patients who had recurrence within 2 years of resection (solid bar, n=16) and those 
who did not (open bar, n=21). Mean+SEM, *P<0.05 compared with the open bar. (H) Representative images of TonEBP immunohistochemical staining 
of non-tumour from tissue arrays processed simultaneously. Staining intensity was assigned to five grades as shown (t0–t4). (I) Kaplan-Meier plot 
of postoperative recurrence in two layers of patients: tNT0 (t0, n=130) versus tNT1 (t1–t4, n=166). (J) Kaplan-Meier plot of postoperative survival 
in two layers of patients tT0 (t0–1, n=80) versus tT1 (t2–4, n=216). (K) HEK293 cells were transfected with microRNA (miR)-223 or NC, followed 
by transfection of a luciferase reporter construct containing 3′-UTR of TonEBP with a putative miR-223-binding site. Luciferase activity is shown in 
mean+SD (n=3). *P<0.05 compared with NC. (L) HepG2 cells were transfected with miR-223 or NC followed by a 12-hour hypoxia or normoxia. 
TonEBP and Hsc70 immunoblotting was performed. DEN, diethylnitrosamine; HCC, hepatocellular carcinoma; mRNA, messenger RNA; NC, non-specific 
control RNA; NT, non-tumour; PBS, phosphate-buffered saline; TonEBP, tonicity-responsive enhancer-binding protein; T, tumour; UTR, untranslated 
region.
agents are HBV, HCV and alcoholic or non-alcoholic fatty liver. 
Genome sequencing, gene expression profiling and histological 
analyses have shown that HCC is widely heterogeneous and 
diverse imposing formidable challenges to effective treatment 
and personalised therapy.3 4
While molecular pathogenesis of HCC is multifaceted, two 
sequential mechanisms predominate.5 First is chronic inflamma-
tion followed by cirrhosis after tissue damage caused by viral 
infection, alcohol or metabolic influences. Next come mutations 
in oncogenes and tumour suppressor genes. Thus, a variety of 
aetiological insults incite common cellular reactions creating a 
microenvironment in which sequential mutations and genetic 
alterations drive formation of dysplastic nodules followed by 
early HCC and ultimately, metastasis. Investigating the microen-
vironment might uncover a common molecular pathway useful 
for a prognostic biomarker and therapeutic target.
Tonicity-responsive enhancer-binding protein (TonEBP), also 
known as NFAT5, is a central component of the inflammatory 
enhanceosome in which TonEBP bridges activated transcription 
factors to histone acetyltransferase p300 on gene promoters.6 
TonEBP expression is stimulated by inflammation leading to 
elevated expression of proinflammatory genes in rheumatoid 
arthritis7 8 and atherosclerosis.9 Although several studies have 
shown that TonEBP is involved in tumour cell migration,10 
TonEBP’s role in tumour development and progression is 
unknown. In this study, we examined TonEBP in hepatic tissues 
obtained from patients with HCC. We found TonEBP expres-
sion to be dramatically elevated in tumours than surrounding 
areas regardless of aetiology in over 90% of patients with HCC 
confirming the general importance of inflammation. Exper-
iments in animals revealed that TonEBP mediates the initial 
hepatic injury in response to environmental insults leading to 
local inflammation, which promotes the development and 
progression of HCC.
MATerIAlS AnD MeTHODS
Human HCC samples and clinical information
A total of 296 patients who underwent hepatic resection 
for HCC from January 2008 to December 2015 at the Ulsan 
University Hospital, University of Ulsan, College of Medicine, 
Ulsan, Korea, were included in the study. All patients were 
HCC treatment naïve before surgery. All 296 patients who 
underwent hepatic resection had a grossly complete resection. 
The patients were predominantly male (84.1%), with average 
age of 56.6 years. The median follow-up period was 31 months 
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Figure 2 TonEBP haplodeficiency is resistant to DEN-induced hepatocarcinogenesis. TonEBP+/Δ mice and their TonEBP+/+ littermates were treated 
with PBS or DEN as in figure 1. (A) Non-tumour regions adjacent to tumours were immunoblotted for TonEBP and Hsc70 from DEN-injected animals. 
(B) Representative liver images from DEN-injected animals. (C) Tumour number, maximal size of tumours and liver weight from PBS-injected (n=8 for 
each genotype) or DEN-injected mice (n=18 for each genotype). Mean+SEM. #P<0.05 compared with corresponding PBS-injected animals. *P<0.05 
compared with DEN-injected TonEBP+/Δ animals. (D) Representative H&E images of hepatic tissues from DEN-injected animals. Magnified images 
on the right are from small boxes on the left. Boxes are in tumours (top and bottom of (i), top of (ii) and (iii)), dysplastic nodule (bottom of (ii)) or 
tumour-free area (bottom of (iii)). (E) real time polymerase chain reaction (RT-qPCR) analyses of TonEBP, inflammatory genes (COX-2, TNFα, IL-1β, 
IL-6, MCP-1), macrophage marker (F4/80), proliferation markers (Ki-67, cyclin D1) and angiogenic factors (HIF-1α, VEGF) in non-tumour regions 
adjacent to tumours in animals from (C). (F) Representative immunohistochemical images of TonEBP and Ki-67. COX-2, cyclo-oxygenase-2; DEN, 
diethylnitrosamine; HIF-1α, hypoxia-inducible factor 1 alpha; IL, interleukin; MCP-1, monocyte chemoattractant protein 1; PBS, phosphate-buffered 
saline; TNFα, tumour necrosis factor alpha; TonEBP, tonicity-responsive enhancer-binding protein; VEGF, vascular endothelial growth factor. 
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Figure 3 Promotion of hepatocarcinogenesis by HFD is tempered by TonEBP haplodeficiency. Animals were injected with DEN as in figure 2, 
followed by feeding with ND or HFD for 30 weeks (online supplementary figure S7). (A) Non-tumour regions adjacent to tumours were immunoblotted 
for TonEBP and Hsc70 in TonEBP+/+ animals. (B) Representative liver images. (C) Top: tumour number, maximal tumour size and maximal tumour 
weight from individual animals fed with ND (n=12 for each genotype) or HFD (n=15 for each genotype). Mean+SEM, *P<0.05 compared with 
corresponding TonEBP+/+. #P<0.05 compared with corresponding ND. Bottom: tumours larger than 3 mm in diameter from representative individual 
animals are shown. (D) Representative images of H&E stained liver tissues from animals fed with HFD. (E) RT-qPCR analyses as in figure 2E. 
(F) Correlation of TonEBP mRNA expression with mRNA expression of COX-2, TNFα and MCP-1 in non-tumour areas of hepatic tissues from 
TonEBP+/+ animals fed with ND (n=10) and HFD (n=10). COX-2, cyclo-oxygenase-2; DEN, diethylnitrosamine; HFD, high-fat diet; MCP-1, monocyte 
chemoattractant protein 1; mRNA, messenger RNA; ND, normal diet; TNFα, tumour necrosis factor alpha; TonEBP, tonicity-responsive enhancer-binding 
protein.
(range=1–105 months). Postoperative recurrence was observed 
in 144 cases (48.7%). The 2-year and 5-year HCC recurrence 
rates were 43.6% and 61.1%, respectively. During postopera-
tive follow-up period, metastasis and death were observed in 
61 (20.6%) and 84 (28.4%) of cases, respectively. Data were 
expressed as mean±SD or median (range). For statistical signif-
icance, Student’s t-test and χ2 test were used for comparisons of 
variables between groups. The cumulative relapse and survival 
rates were evaluated by the Kaplan-Meier method, and differ-
ences were determined by the log-rank test. A multivariate anal-
ysis was carried out to identify the independent predictor for 
recurrence and survival using the Cox regression hazard model. 
All data were analysed using the statistical package SPSS for 
Windows V.21.0. In all cases, a two-tailed P value less than 0.05 
was considered statistically significant. Additional protocols and 
procedures are described in online supplementary methods.
Mice
All the methods involving live mice were carried out in accor-
dance with the approved guidelines. All experimental proto-
cols were approved by the Institutional Animal Care and Use 
Committee of the Ulsan National Institute of Science and Tech-
nology (UNISTACUC-12-15-A).
All experiments were performed in male C57BL/6 mice. To 
induce HCC, we administrated a single intraperitoneal injec-
tion of 25 mg/kg diethylnitrosamine (DEN) (N0756; Sigma) to 
2-week-old mice and euthanised them at 9 months of age. In 
the obesity-amplified DEN-induced HCC model, DEN (25 mg/
kg) was injected intraperitoneally into 2-week-old mice. After 
4 weeks, mice were separated into two dietary groups and fed 
either normal diet (10% fat as kilocalories, Research Diets, 
New Jersey, USA) or high-fat diet (HFD; 60% fat as kilocalo-
ries, Research Diets) and euthanised for 36 weeks dietary period. 
Tumour incidence and size were blindly calculated.
C57BL/6 TonEBPf/f mice11 were bred with Alb-Cre mice or 
LysM-Cre to generate TonEBPf/f:Alb-Cre or TonEBPf/f:LysM-Cre, 
respectively. To induce liver injury, TonEBPf/f:Alb-Cre or TonEB-
Pf/f:LysM-Cre mice and their wild type (WT) littermates were 
intraperitoneally injected single DEN (100 mg/kg) and euthanised 
after 48 hours. For lipopolysaccharide (LPS)-induced liver injury, 
TonEBPf/f:Alb-Cre mice were intraperitoneally coinjected with 
LPS (5 g/kg of body weight) and D-galactosamine (400 mg/kg of 
body weight) and euthanised after 4 hours.
Ethanol feeding-induced liver injury and fat accumulation was 
demonstrated as described.12 Briefly, mice were acclimated liquid 
diet feeding with the control Lieber-DeCarli diet (Bio-Serv) ad 
libitum for 5 days, followed by ethanol Lieber-DeCarli diet 
(Bio-Serv) containing 5% (vol/vol) ethanol supplemented with 
maltose dextrin or isocaloric control diet for 10 days. To syner-
gistically induce liver injury and inflammation, on day 11, mice 
were gavaged with a single dose of ethanol (5 g/kg) or isocaloric 
dextrin-maltose at 08:00 and sacrificed 9 hours later.
Cell line
HCC cell line, HepG2, from American Type Culture Collection 
was maintained in modified Eagle’s medium (MEM; Hyclone) 
supplemented with 10% fetal bovine serum (FBS; Thermo) 
with penicillin–streptomycin (Hyclone). Cells were transfected 
with TonEBP small interfering (si)RNA or control scrambled 
siRNA using Lipofectamine RNAiMAX (Invitrogen) following 
the manufacturer’s instructions. Cells were transfected with 
micro-RNA (miRNA)-223 or control miRNA using Lipofect-
amine 2000 (Invitrogen) following the manufacturer’s instruc-
tions. Mouse embryo fibroblasts (MEFs) and HEK293 cells 
were cultured in Dulbecco’s MEM supplemented with 10% 
FBS (Thermo) with penicillin–streptomycin (Hyclone). MEFs 
were established from the TonEBPΔ/Δ mouse. For binding assays, 
HEK293 cells were transfected with plasmids using Lipofect-
amine 2000 (Invitrogen) following the manufacturer’s instruc-
tions. For hypoxia challenge, HepG2 cells were incubated in 
hypoxic chamber in 2% O2. Additional protocols and proce-
dures are described in online supplementary methods.
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Figure 4 Liver injury and inflammation are tempered by hepatocyte-specific TonEBP deficiency. (A–D) TonEBPfl/fl; Albumin cre+/− mice (HKO) and 
their TonEBPfl/fl; Albumin cre−/− (WT) littermates were injected with DEN or PBS. Livers and serum samples were analysed 48 hours later. (A) Livers from 
the WT animals were immunoblotted for TonEBP and Hsc70. (B) Serum ALT levels in PBS-treated (n=5) and DEN-treated animals (n=8). Mean+SEM. 
*P<0.05 compared with WT. (C) TUNEL signal in hepatic tissues. (D) RT-qPCR analyses of TonEBP, inflammatory genes (COX-2, TNFα, IL-1β, IL-6) 
and proliferation markers (Ki-67, cyclin D1) in livers of DEN-treated animals. mRNA abundance was expressed relative to WT group. P, PBS; D, DEN. 
Mean+SEM, #P<0.05 compared with corresponding P. *P<0.05 compared with WT. (E) Immunoblotting of liver samples, three from each genotype, 
for TonEBP, PCNA, Hsc70, caspase-3, C-Casp-3, COX-2 and iNOS. (F,G) HKO and WT animals were injected with PBS or LPS (5 µg/kg) in combination 
with D-galactosamine (400 mg/kg) (LPS). The animals were analysed 4 hour later. (F) Serum levels of ALT and AST. (G) RT-qPCR analysis mRNA levels. 
mRNA abundance was expressed relative to WT, PBS group. Mean+SEM, *P<0.05 compared with WT. #P<0.05 compared with PBS. (H–J) The animals 
were fed with Con or EtOH for 10 days. (H) Serum ALT, AST and LDH levels. *P<0.05 compared with WT. #P<0.05 compared with corresponding Con-
fed animals. (I) RT-qPCR analyses of TonEBP and inflammatory genes in livers. (J) Representative images of H&E of hepatic tissues from animals from 
(H). ALT, alanine transaminase; AST, aspartate aminotransferase; C-Casp-3, cleaved caspase-3; iNOS, inducible nitric oxide synthase; Con, control 
diet; COX-2, cyclo-oxygenase-2; DEN, diethylnitrosamine; EtOH, ethanol diet; HKO, hepatocyte-specific TonEBP knockout; IL, interleukin; LDH, lactate 
dehydrogenase; LPS, lipopolysaccharide; mRNA, messenger RNA; PBS, phosphate-buffered saline; TNFα, tumour necrosis factor alpha; TonEBP, tonicity-
responsive enhancer-binding protein; WT, wild type.
Statistical analysis
Data are presented as means+SD or means+SEM as indicated. 
Differences between groups were analysed by Student’s t-test, 
and statistical significance was considered at *P<0.05.
reSulTS
Hepatic TonebP predicts postoperative prognosis in patients 
with HCC
In macrophages, TonEBP expression is markedly stimulated by 
inflammatory signals.6 Since inflammation is an essential feature 
of HCC,13 14 we investigated hepatic TonEBP expression in 
DEN-induced mouse HCC. Expression of TonEBP messenger 
RNA (mRNA) in non-tumour regions surrounding tumours 
(non-tumour TonEBP mRNA expression) was higher compared 
with normal hepatic tissues while lower compared with adjacent 
tumour (figure 1A). TonEBP expression was higher in tumours 
compared with non-tumour regions and localised to the nuclei of 
hepatocytes (figure 1B,C and online supplementary figure 1A). 
Interestingly, non-tumour TonEBP mRNA expression correlated 
significantly with tumour numbers (figure 1D) consistent with 
the importance of inflammation in HCC.
We examined hepatic tissues obtained from 296 patients 
with HCC  (online supplementary table 1). As in the animals, 
TonEBP mRNA expression was higher in tumours compared with 
non-tumour regions (online supplementary figure 1B). Immu-
nohistochemical analyses (figure 1E and online supplementary 
figure 1C) revealed the same pattern of changes in 92.6% of 
the patients (274/296). This elevation was observed regardless of 
aetiology (figure 1F). Interestingly, non-tumour TonEBP mRNA 
expression was higher in patients who had early recurrence 
compared with patients who did not (figure 1G). These observa-
tions suggest importance of TonEBP in tumourigenesis, and that 
non-tumour TonEBP promotes postoperative recurrence.
Given the importance of TonEBP, we investigated the role 
of TonEBP further by stratification of the patients according 
to their TonEBP expression (figure 1H). Univariate analysis of 
two layers of patients showed that higher non-tumour TonEBP 
expression was significantly associated with bigger tumour, 
advanced tumour grade, recurrence, metastasis (ie, extrahepatic 
metastasis) and protein induced by higher vitamin K absence or 
antagonist II (PIVKA II) and HBV DNA level (online supplemen-
tary table 2). Kaplan-Meier plot confirmed the higher recurrence 
(figure 1I) and metastasis (online supplementary figure 2A) in 
patients with higher non-tumour TonEBP expression. Likewise, 
higher tumour TonEBP expression was associated with advanced 
tumour grade, microvascular invasion, recurrence, metastasis, 
death and higher PIVKA II level (online supplementary table 
3). Again, Kaplan-Meier plot confirmed the lower survival 
(figure 1J) and higher metastasis and recurrence (online supple-
mentary figure 2C,D) in patients with higher tumour TonEBP 
expression. These observations suggest that TonEBP promotes 
various aspects of tumourigenesis and progression.
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Figure 5 TonEBP-dependent stimulation of COX-2 requires transcription factor YY1. (A) TonEBP versus COX-2 mRNA abundance in tumours from 25 
patients with HCC. (B) Immunohistochemical images of COX-2 and TonEBP in consecutive hepatic sections from two representative patients with HCC. 
(C) Immunoblots of livers from TonEBP+/Δ (+/Δ) and their TonEBP+/+ littermates (+/+) from figure 2A. (D) Immunoblots of HepG2 cells transfected 
with siRNA followed by treatment with IL-1β. (E) Serum PGE2 levels in PBS-treated (n=5) or DEN-treated mice (n=8 for each genotype) from figure 2. 
Mean+SEM. *P<0.05 compared with TonEBP+/+. #P<0.05 compared with PBS-injected mice. Serum PGE2 levels in mean+SEM. *P<0.05 compared with 
DEN-injected TonEBP+/Δ animals. (F) Lysates of HepG2 cells treated with IL-1β or not (con) as indicated were immunoprecipitated (IP) with normal 
IgG, anti-YY1 IgG (YY1), normal serum (S) or anti-TonEBP serum (T). The immunoprecipitates and cell lysates were immunoblotted as indicated. (G) 
HepG2 cells were transfected with siRNA indicated followed by transfection with pGL3 (vector), COX-2 (COX-2 promoter reporter in pGL3) or ΔYY1 
(COX-2 whose YY1 binding site was disabled by mutagenesis) (n=3). (H) HepG2 cells were treated with IL-1β as indicated. ChIP was performed using 
anti-TonEBP IgG, anit-YY1 IgG or normal IgG. YY1 binding region in the COX-2 promoter was quantified using RT-qPCR. Means of two independent 
experiments are shown. (I) HepG2 cells were transfected with siRNA and treated with IL-1β. ChIP was performed with anti-YY1 IgG. Means of two 
independent experiments are shown. (J) Nuclear extracts were prepared from HepG2 transfected with siRNA followed by treatment with IL-1β as 
indicated. Electrophoretic mobility shift assay was performed (see supplementary material and methods). Anti-YY1 IgG or normal IgG was used to 
supershift the YY1–DNA complex (right). (K) Lysates of HepG2 cells treated with IL-1β were immunoprecipitated. Lysates and immunoprecipitates 
were immunoblotted for p300 and YY1. (L) Cells transfected with siRNA were immunoprecipitated as above. (M) MEFs from TonEBP+/+ (+/+) and 
TonEBPΔ/Δ mouse (Δ/Δ) were immunoprecipitated. ChIP, chromatin immunoprecipitation; COX-2, cyclo-oxygenase-2; DEN, diethylnitrosamine; HCC, 
hepatocellular carcinoma; IL, interleukin; MEF, mouse embryo fibroblast; mRNA, messenger RNA; PBS, phosphate-buffered saline; PGE2, prostaglandin 
E2; siRNA, small interfering RNA; TonEBP, tonicity-responsive enhancer-binding protein. 
We further investigated TonEBP’s role in postoperative prog-
nosis by multivariate analyses. As for recurrence, tumour size, 
microvascular and lymphovascular invasion along with non-tu-
mour TonEBP expression displayed strong association (table 1). 
Male sex, alanine transaminase levels, albumin levels, tumour 
size, tumour grade, microvascular invasion and non-tumour 
TonEBP expression showed robust association with metastasis. 
Finally, microvascular invasion, albumin levels and TonEBP 
expression in tumour were significantly associated with overall 
survival. We conclude that hepatic TonEBP expression predicts 
postoperative recurrence, metastasis and death in patients 
with HCC.
Hepatic induction of TonebP is mediated by a fall in the mir-
223 abundance
Elevated TonEBP expression is critical for the HCC develop-
ment and progression. Previous studies showed that miR-223 
expression was dramatically suppressed in HCC regardless of 
aetiology,15 likely due to local hypoxia (online supplementary 
figure 3A).16 17 As expected, miR-223 abundance was reduced in 
tumour regions compared with non-tumour regions in patients 
with HCC  (online supplementary figure 3B) and DEN-induced 
HCC (online supplementary figure 3C). Since TonEBP gene is a 
target of miR-223 in mouse macrophages,18 we asked whether 
the hypoxia-mediated fall in miR-223 abundance was responsible 
for the elevated TonEBP expression. miR-223 interacted with 
the 3′-untranslated region of human TonEBP mRNA (figure 1K) 
and lowered the abundance of TonEBP (online supplementary 
figure 3D,E) both in normoxia and hypoxia (figure 1L). Thus, 
suppression of miR-223 contributes to the elevated expression 
of TonEBP in HCC.
TonebP promotes HCC initiation and growth via oxidative 
stress and inflammation
Since hepatic TonEBP expression was closely associated with the 
number of tumours in a mouse model of HCC (figure 1D), we 
next investigated the role of TonEBP in HCC using a line of 
mice with TonEBP haplodeficiency—TonEBP+/Δ (figure 2A).19 
Number of tumours and maximal tumour size were both signifi-
cantly smaller in the TonEBP+/Δ animals than their TonEBP+/+ 
littermates (figure 2B,C) in association with reduced liver injury 
(online supplementary table 4). Histological examinations 
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Figure 6 TonEBP and YY1 interact via RHD and spacer. (A) Diagrams 
of TonEBP and YY1 and their deletion constructs. (B–E) Lysates from 
HEK293 cells transfected with Myc-TonEBP plus Flag-YY1 (B) or various 
recombinant fragment of Flag-YY1 (C), Myc-Yc1 plus or Flag-YY1 or 
Flag-YY1-ΔS (D) or Flag-YY1 plus Myc-TonEBP or Myc-TonEBP-ΔRHD 
(E) were immunoprecipitated with normal IgG, anti-Flag IgG or anti-
Myc IgG as indicated. The immunoprecipitates (upper) and lysates 
(bottom) were immunoblotted as indicated. (F) Model of TonEBP actions 
in the pathogenesis of HCC. First, TonEBP mediates oxidative stress-
induced cell injury and local inflammation. Second, TonEBP expression 
is enhanced by oxidative stress. On the promoter of the COX-2 gene, 
the elevated TonEBP recruits the acetyltransferase p300 to YY1 in 
a manner dependent on IL-1β. TonEBP promotes tumourigenesis, 
recurrence and metastasis via PGE2 and possibly other pathways 
(broken line). See text for details. COX-2, cyclo-oxygenase-2; Flag, anti-
Flag IgG; GA rich, glycine-alanin rich; GK rich, glycine-lysine rich; HCC, 
hepatocellular carcinoma; IB, immunoblot; IgG, normal IgG, Myc, anti-
Myc IgG; PGE2, prostaglandin E2; IL, interleukin; IP, immunoprecipitated; 
LPS, lipopolysaccharide; RHD, Rel-homology domain; TonEBP, tonicity-
responsive enhancer-binding protein. 
typically revealed smaller tumours (figure 2D(i)), smaller 
dysplastic nodules (figure 2D(ii)) and often absence of tumours 
(figure 2D(iii)) in the TonEBP+/Δ animals. Since chronic inflam-
mation leads to cirrhosis followed by HCC,20 we examined 
hepatic inflammation. Expression of proinflammatory and 
angiogenic genes was strikingly elevated in HCC mice along 
with TonEBP (figure 2E), indicating the association of elevated 
TonEBP expression with inflammation. As expected, expression 
of these genes was significantly lower in the TonEBP+/Δ animals 
indicating that TonEBP promoted tumour initiation and growth 
in association with inflammation and liver injury. In patients 
with HCC, the association between TonEBP and inflammation 
was confirmed from analysis of the RNA-seq dataset from TCGA 
(online supplementary figure 4).
We noted that proliferation markers were elevated in the 
mouse model of HCC (figure 2E,F). Inflammatory cytokines are 
known to promote tumour growth. Interestingly, manipulation 
of TonEBP expression led to parallel changes in proliferation of 
HepG2 cells (online supplementary figure 6B,C). Overexpres-
sion of TonEBP stimulated proliferation of neighbouring naïve 
cells (online supplementary figure 6D,E), suggesting that para-
crine factors contributed to the TonEBP-dependent stimulation 
of proliferation. These results provide mechanistic basis for 
the role of TonEBP on the tumour growth. We conclude that 
TonEBP promotes tumour initiation and growth via oxidative 
stress-induced cell injury and inflammation.
DEN causes oxidative stress21 leading to hepatic cell death 
which, in turn, evokes local inflammation.22 23 TonEBP was 
induced by hypoxia (figure 1M) and H2O2 (online supplemen-
tary figure 5A). Knockdown of TonEBP reduced cell injury 
(online supplementary figure 5B,C) and inflammation (online 
supplementary figure 5D) in response to H2O2. Thus, TonEBP 
mediates cell injury and inflammation in response to oxidative 
stress.
TonebP is involved in obesity-induced tumour initiation and 
growth
Epidemiological studies have shown that obesity increases cancer 
risk.24–26 Obesity-induced chronic inflammation is a major factor 
contributing to the increased HCC risk.27 Because the data 
discussed above showed that TonEBP promoted tumour initia-
tion and growth via inflammation, we examined obesity-induced 
HCC (online supplementary figure 7A). TonEBP+/Δ animals 
were lighter than their WT littermates both in DEN-treated and 
PBS-treated groups up to the 12th week of HFD feeding (online 
supplementary figure 7B). In the DEN-treated group, distinct 
change took place. After the 26th week, there was a reversion 
where the TonEBP+/Δ became significantly heavier than their WT 
littermates because of smaller weight loss. During the reversal 
of body weight, high blood glucose levels in the WT littermates 
disappeared (online supplementary figure 7C,D). These changes 
are likely due to differences in tumour burden.
HFD feeding increased hepatic non-tumour TonEBP 
expression (figure 3A) along with more and bigger tumours 
(figure 3B–D), elevated expression of proinflammatory genes, 
proliferation markers (figure 3E) and liver injury (online supple-
mentary table 5). TonEBP haplodeficiency was associated with 
fewer and smaller tumours, reduced expression of proinflam-
matory genes (which correlated with expression of TonEBP 
(figure 3F)) and proliferation markers, and milder liver injury 
expression providing strong evidence that TonEBP is involved 
in the obesity-induced inflammation and hepatocellular 
carcinogenesis.
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TonebP in hepatocytes and macrophages mediates Den-
induced cellular injury and inflammation
The data discussed above show that TonEBP promotes inflam-
mation critical in tumour initiation and growth. Since DEN 
results in cellular injury leading to inflammation and even-
tually HCC,21 we examined TonEBP’s role in hepatic injury 
using a line of mice with hepatocyte-specific TonEBP knockout 
(HKO).11 Hepatic TonEBP expression, especially TonEBP 
immunohistochemical signal in hepatocytes, was dramatically 
reduced in these animals (online supplementary figure 8A,B). In 
WT mice, hepatic TonEBP is elevated 48 hours after DEN treat-
ment (figure 4A) consistent with oxidative injury. DEN-induced 
hepatic injury was reduced in the HKO animals compared 
with WT littermates (figure 4B), manifested by lower terminal 
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) 
signal (figure 4C) and caspase-3 activity (figure 4E). Expres-
sion of Ki-67 and proliferating cell nuclear antigen (PCNA) 
was significantly lower in the HKO after DEN treatment along 
with proinflammatory genes (figure 4D,E). Phosphorylation 
of mitogen activated-protein kinase (MAPKs) was not affected 
(online supplementary figure 8C), indicating that upstream 
signalling was not affected in the HKO. Taken together, 
hepatocyte TonEBP mediates DEN-induced hepatic injury and 
inflammation.
As TonEBP is a critical regulator of the proinflammatory 
activation of macrophages,6 28 we examined the role of macro-
phage TonEBP using a line of mouse with myeloid-specific 
TonEBP knockout (MKO).6 These animals displayed normal 
TonEBP expression in hepatocytes (online supplementary figure 
8D). DEN-induced hepatic injury, inflammation and prolifera-
tion were reduced in the MKO compared with WT littermates 
(online supplementary figure 8E,F). These data demonstrate 
that macrophage TonEBP also contributes to the DEN-induced 
hepatic injury and inflammation.
TonebP mediates lPS-induced and alcohol-induced hepatic 
inflammation
We asked whether TonEBP mediates inflammation induced by 
agents other than DEN. First, we examined LPS which leads to 
hepatocyte death and inflammation.29 LPS-responsive hepatic 
injury (figure 4F) and inflammation (figure 4G) were tempered 
in the HKO. The effect of TonEBP on LPS-induced inflammation 
was confirmed in HepG2 cells (online supplementary figure 9A).
Alcohol causes leakage of LPS from gut into circulation leading 
to hepatic inflammation.30 Since alcoholic hepatitis is a risk 
factor for HCC31 and TonEBP mediates LPS-induced hepatocyte 
inflammation as discussed above, the role of TonEBP in alco-
hol-induced hepatic injury was examined. The chronic and binge 
alcohol feeding resulted in hepatic damage, inflammation and 
fat accumulation (figure 4H–J). Hepatic inflammation and injury 
were reduced in the HKO animals (figure 4H,I) without signifi-
cant changes in fat accumulation (figure 4J). These data demon-
strate that hepatocyte TonEBP mediates alcohol-induced hepatic 
injury and inflammation to which the TonEBP-mediated LPS-re-
sponsive hepatic inflammation described above contributes.
To understand the role of TonEBP in hepatic inflammation 
in general, we analysed inflammatory stimuli-responsive inflam-
mation. Interleukin (IL)-1β- or tumour necrosis factor alpha-in-
duced inflammation was attenuated in TonEBP-deficient HepG2 
cells (online supplementary figure 9B,C) and non-cancerous 
alpha mouse liver (AML)-12 cells (online supplementary figure 
9D). Taken together, these data demonstrate that TonEBP is a 
general mediator of hepatic inflammation induced by diverse 
agents, consistent with elevated TonEBP expression regardless 
the cause of HCC (figure 1G).
TonebP promotes COX-2 expression in a YY1-dependent 
manner
Transcriptional targets of the inflammatory enhanceosome, 
in which TonEBP is a limiting component, include cyclo-oxy-
genase-2 (COX-2).6 We investigated COX-2 because it promotes 
tumourigenesis,32–34 and COX-2 expression in patients 
with HCC  correlates with postoperative recurrence35 like 
TonEBP. In patients with HCC, COX-2 expression was elevated 
in tumour regions compared with non-tumour regions (online 
supplementary figure 10A). TonEBP expression correlated posi-
tively with COX-2 expression (figure 5A,B and online supple-
mentary table 6). TonEBP deficiency resulted in reduced COX-2 
expression (figure 5C,D and online supplementary figure 10B,C) 
leading to reduced production of prostaglandin E2 (PGE2) in 
various animal models (figure 5E and online supplementary 
figure 10D–F) and HepG2 cells (online supplementary figure 
10G). Altered TonEBP expression by hypoxia and miR-223 
was accompanied by parallel changes in the COX-2 expression 
(online supplementary figure 10H). In addition, the TonEBP-de-
pendent stimulation of proliferation (online supplementary 
figure 6D,E) was dependent on COX-2 (online supplementary 
figure 10I). These data demonstrate that TonEBP promotes 
tumourigenesis and recurrence by, at least in part, the stimula-
tion of COX-2 expression.
To understand the molecular mechanism underlying the regu-
lation of COX-2, promoter reporters were constructed using 
human sequence. Initial analyses showed that TonEBP stimu-
lated the COX-2 promoter without DNA binding to its cognate 
sites (online supplementary figure 11A,B). We hypothesised that 
TonEBP might be a transcriptional cofactor of a DNA-binding 
protein within 1 kb from the transcription start site. To iden-
tify such a protein, TonEBP-interacting proteins were identified 
using liquid chromatography–tandem mass spectrometry. One of 
the proteins picked by the procedure was the transcription factor 
YY1 (data not shown). We confirmed that YY1 and TonEBP were 
mutually coimmunoprecipitated; plus the interactions were stim-
ulated by IL-1β without changes in their expression (figure 5F). 
Knockdown of TonEBP or YY1 blunted the induction of COX-2 
mRNA by IL-1β to the same extent, but the effect of double 
knockdown was not additive (online supplementary figure 11C). 
TonEBP-dependent COX-2 promoter activity was dependent on 
the YY1 binding site (figure 5G) demonstrating that TonEBP 
action required DNA binding of YY1.
TonebP promotes YY1 recruitment to the COX-2 promoter in 
response to inflammation
Chromatin immunoprecipitation (ChIP) was performed to inves-
tigate the interaction of YY1 and TonEBP at the COX-2 promoter 
in situ. Interestingly, YY1 bound to its putative binding site of 
the COX-2 promoter in an IL-1β-dependent manner along with 
TonEBP (figure 5H) consistent with their interactions. Knock-
down of TonEBP dramatically reduced of YY1 binding to the 
promoter (figure 5I), whereas YY1 expression (online supple-
mentary figure 11D), nuclear translocation (online supplemen-
tary figure 11E) and binding to its promoter site (figure 5I) were 
not affected. Thus, YY1 binding to its cognate site in the COX-2 
promoter requires TonEBP.
TonEBP is responsible for the recruitment of the histone acet-
yltransferase p300, a critical regulator of COX-2 transcription,36 
to the inflammatory enhanceosome.6 Here, we found that YY1 
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interacted with p300 in HepG2 cells and the interaction showed 
an IL-1β responsiveness (figure 5K) as well as TonEBP depen-
dence (figure 5L), indicating that YY1 was incorporated into 
the inflammatory enhanceosome on the COX-2 promoter. This 
observation was supported by reduced interaction between YY1 
and p300 in TonEBPΔ/Δ MEF cells where the protein product of 
the TonEBPΔ allele does not interact with p300.6
To characterise the interaction between TonEBP and YY1, we 
performed coimmunoprecipitation experiments. Overexpressed 
TonEBP and YY1 were mutually pulled down by each other 
(figure 6B). Coimmunoprecipitation with overexpressing various 
recombinant YY1 proteins (figure 6A) revealed that the spacer 
domain of YY1 was critical for the interaction with TonEBP 
(figure 6C). Next, Yc1, an N-terminal-truncated TonEBP with 
intact Rel-homology domain (RHD) (figure 6A) interacted with 
YY1 in a spacer-dependent manner (figure 6D), indicating that 
the C-terminal two-thirds of TonEBP was dispensable for the 
interaction. Deletion of RHD domain abolished the interaction 
with YY1 (figure 6E), indicating the importance of RHD. Thus, 
the interaction between TonEBP and YY1 is mediated by RHD 
and spacer domain.
In summary, local inflammation stimulates the assembly of 
an enhanceosome on the COX-2 promoter (figure 6F, bottom). 
This assembly is dependent on YY1 binding to its cognate site 
on DNA. Of interest, TonEBP is required for the recruitment of 
both YY1 and p300 to the promoter in situ. The critical role of 
TonEBP in PGE2 production provides a mechanistic basis for the 
strong association of hepatic TonEBP with postoperative recur-
rence, metastasis and death in patients with HCC.
DISCuSSIOn
Given that HCC is a heterogeneous disease with diversity in aeti-
ological agents, tumour architectures, histological characteristics, 
repertoire of oncogenic mutations and gene expression profiles, 
it is remarkable that elevated TonEBP expression in tumours over 
non-tumour regions is observed in more than 90% of patients 
with HCC. TonEBP is more prevalent than any other immuno-
histochemical biomarker of HCC and the first one associated 
with inflammation.37 38 The widespread elevation in tumour 
TonEBP levels demonstrates that inflammation is the common 
feature of heterogeneous HCC. In the cohort of patients with 
HCC studied here, higher tumour TonEBP expression predicts 
death and is associated with tumour size, grade, recurrence and 
metastasis. COX-2 expression is driven by the elevated TonEBP 
leading to the production of PGE2 which promotes tumouri-
genesis and progression,32–34 providing a mechanistic basis for 
the TonEBP as a part of the common pathway activated by the 
diverse aetiological agents (figure 6F).
Hepatic resection has been the treatment of choice for 
early HCC. However, resection is associated with a 70% 
recurrence rate in the remaining hepatic tissue.39 Postoper-
ative recurrence is classified as early or late depending on 
whether the recurrence occurs within 2 years of resection 
or not. Remarkably, TonEBP mRNA expression was higher 
in the non-tumour regions of patients who had early recur-
rence compared with those who did not. In the cohort of 
patients with HCC, higher non-tumour TonEBP expression 
predicts recurrence and metastasis and is associated with 
tumour size and grade. We observe COX-2 expression is also 
driven by TonEBP in this region. PGE2 is known to educate 
inflammatory tumour microenvironment to promote 
tumour progression by orchestrating crosstalk between 
tumour cells and their microenvironment.32–34 Thus, the 
TonEBP–COX-2–PGE2 pathway contributes to recurrence. 
Given the complexity of cellular mechanisms involved in 
recurrence,39 we suspect that there might be other pathways 
of TonEBP such as cell migration10 that contribute to recur-
rence (figure 6F).
Studies in various mouse models of HCC and hepatitis 
reveal additional TonEBP actions upstream of inflammation. 
The diverse insults that cause HCC impose oxidative stress40 
leading to cell injury and inflammation. Experiments with 
TonEBP-deficient animals and cultured hepatocytes demon-
strate that TonEBP promotes the cell injury and inflammation 
in response to oxidative stress (figure 6F). In addition, TonEBP 
expression is dramatically elevated in response to oxidative 
stress providing a positive reinforcement. Thus, TonEBP is 
intrinsically involved in multiple steps in the cellular path-
ways stimulated by the various insults that cause HCC. This 
explains the strong association of hepatic TonEBP and poor 
prognosis in patients with HCC. On the other hand, since 
our patient cohort is heavily biased to HBV-driven HCC, the 
association needs more robust verification in patients with 
other aetiologies.
The data presented here suggest that targeting TonEBP 
is an attractive strategy to prevent recurrence as well 
as hepatocarcinogenesis and metastasis. In this regard, 
three distinct action sites of TonEBP can be considered 
(figure 6F): (1) cell injury and inflammation; (2) induc-
tion of TonEBP by oxidative stress and downregulation of 
miR-223 and (3) transcriptional stimulation of COX-2 and 
other proinflammatory genes. We reported that a small 
compound cerulenin inhibited the transcriptional stim-
ulation of proinflammatory genes including COX-2 by 
blocking the interaction of TonEBP and p300.6 We find that 
cerulenin blocks the IL-1β-induced transcription of COX-2 
in hepatocytes (data not shown). Cerulenin and other 
agents that target any of the three sites of TonEBP action 
might be proved efficacious in preventing recurrence and 
metastasis for patients with HCC whose hepatic TonEBP 
expression is high.
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